MRK vs BMY
By Alex · Tickerpine
Merck & Co., Inc. vs Bristol-Myers Squibb Company, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | BMY |
|---|---|---|
| Price | $156.45 | $67.92 |
| Market cap | $385.99B | $138.74B |
| P/E ratio | 120.3 | 15.0 |
| ROE | 6.96% | 46.60% |
| Profit margin | 4.77% | 18.87% |
| Revenue growth | 5.10% | 5.70% |
| Dividend yield | 2.26% | 3.75% |
| Beta | 0.21 | 0.23 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs BMY in plain English
- MRK is the bigger company — about 2.8× the market cap of BMY.
- BMY is cheaper on earnings (P/E 15.0 vs 120.3).
- BMY earns a higher return on equity (47% vs 7%).
- BMY is growing revenue faster (6% vs 5%).
- BMY has the higher dividend yield (3.75% vs 2.26%).
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
BMY return calculator
See what $1,000 in Bristol-Myers Squibb Company would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.